WuXi Biologics to build 1.3m-sq-ft manufacturing centre

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Lovelyday12)
(Image: Getty/Lovelyday12)

Related tags: Wuxi biologics, China, I-Mab

WuXi Biologics announces its latest expansion, with plans for a drug development and commercial manufacturing site with a potential bioreactor capacity of 144,000L.

The manufacturing centre for biologics will be located in Chendu, a city in southwest China, which on completion, will become the largest such site in the region.

The site will cover 1.3 million-square-feet and house WuXi Biologics’ twelfth drug substances manufacturing facility. The site will house drug development and commercial manufacturing facilities as well.

Upon completion, the contract development and manufacturing organisation (CDMO) stated that it would hold bioreactor capacity of 48,000L but noted that this would be the ‘initial’ capacity. A spokesperson for WuXi Biologics confirmed that this holds the potential to be increased threefold.

Chris Chen, CEO of WuXi Biologics, stated, “Supported by 205 ongoing biologics projects using WuXi Biologics’ open-access and proprietary platforms as well as our unique manufacturing paradigm of ‘Global Dual Sourcing within WuXi Bio’, we will continue to expand manufacturing capacity, based on our portfolio needs, to provide a robust and premier global supply chain that can enable our partners and benefit patients worldwide.”

The suggestion that the company will continue to expand its capabilities, even after such a large facility commitment, mirrors the activities that WuXi Biologics has undertaken in recent years, with 2018 seeing a series of announcements of global investments.

Within China, the company only recently announced that it had broken ground on a $240m (€203m) manufacturing facility​ close to Beijing, which also possessed 48,000L bioreactor capacity.

While the CDMO has also expanded its global footprint, with facilities being built in Singapore​ and Ireland​.

The company suggested that the increased capacity generated by the facility would enable it to acquire further partners, with it recently announcing its first commercial manufacturing agreement with US-based Amicus​ and an extended collaboration with i-Mab​, a Chinese biotech.

Related news

Show more

Related products

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Fill-Finish Biologics

Fill-Finish Biologics

Curia | 16-May-2022 | Technical / White Paper

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for...

Related suppliers

Follow us


View more